AGP Executive Report
Last update: 7 hours agoHIV Prevention: The FDA has granted tentative approval for the first generic long-acting injectable lenacapavir. Priced at $40 per person per year for eligible low- and middle-income countries, initial supplies are expected by year-end, with wider availability in 2027. Health Technology: The Central African Republic and Russia signed health cooperation agreements covering medical training, modern technologies, joint research and digital health, alongside work to prevent and respond to infectious disease threats. Mineral Processing: CVMR has launched a 25-year partnership with the CAR aimed at developing local mineral processing and refining, so more value can be retained in-country. Ebola Monitoring: With the outbreak in neighbouring DRC surpassing 10,000 confirmed cases, the CAR has tightened border health checks; African health ministers are backing surveillance and cross-border coordination rather than border closures.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.